Healionics

Healionics is a private, clinical-stage medical device company pioneering a novel synthetic biomaterial platform called STAR (Sphere Templated Angiogenic Regeneration). Its lead product, the STARgraft vascular graft, is designed to address the critical unmet needs of infection and occlusion in dialysis access, having received FDA Breakthrough Device designation based on promising human study data. The company leverages its deep roots in Seattle's dialysis innovation ecosystem to advance a solution that could significantly improve patient outcomes and reduce the high cost of dialysis care. Healionics appears to be in a late-stage development phase, positioning its lead graft for potential regulatory submission and commercialization.

STAR® (Sphere-Templated Angiogenic Regeneration) biomaterial scaffold, a synthetic porous material engineered with a specific pore size and structure to promote angiogenesis, minimize foreign body response/scarring, and impart high resistance to infection.

Healionics competes in the vascular access graft market against large, established players like Becton Dickinson (BD) and W. L. Gore & Associates, who market traditional ePTFE grafts. Its primary competitive advantage is the demonstrated reduction in infection and occlusion offered by its novel STAR biomaterial, a claim not made by existing synthetic grafts. It also competes with the surgical preference for native arteriovenous fistulas.